Anbio Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	5.35	11.76	9.69	7.1	4.18
Short-Term Investments	8.08	-	-	1.57	-
Cash & Short-Term Investments	13.43	11.76	9.69	8.67	4.18
Cash Growth	30.25%	21.40%	11.75%	107.33%	-
Accounts Receivable	3.72	1.06	1.88	-	0.72
Inventory	-	-	-	0.35	-
Other Current Assets	10.54	5.71	4.18	4.92	0.02
Total Current Assets	27.68	18.53	15.75	13.94	4.92
Net Property, Plant & Equipment	-	-	-	0.01	-
Other Long-Term Assets	-	0.39	0.06	0	-
Total Assets	27.68	18.92	15.81	13.96	4.92
Accounts Payable	0.06	1.63	0.83	1.41	1.89
Unearned Revenue	-	-	-	-	0.49
Other Current Liabilities	0.07	0.1	0.17	0	-
Total Current Liabilities	0.13	1.73	0.99	1.41	2.38
Total Liabilities	0.13	1.73	0.99	1.41	2.38
Common Stock	0.01	0.01	0.01	-	-
Additional Paid-in Capital	6.56	0	0	-	-
Retained Earnings	20.97	17.17	14.8	12.55	2.54
Shareholders' Equity	27.55	17.19	14.82	12.55	2.54
Total Liabilities & Equity	27.68	18.92	15.81	13.96	4.92
Net Cash (Debt)	13.43	11.76	9.69	8.67	4.18
Net Cash Growth	14.18%	21.40%	11.75%	107.33%	-
Net Cash Per Share	0.31	0.28	0.45	86690.56	41813.25
Book Value	27.55	17.19	14.82	12.55	2.54
Book Value Per Share	0.64	0.41	0.69	125469.90	25358.13
Tangible Book Value	27.55	17.19	14.82	12.55	2.54
Tangible Book Value Per Share	0.64	0.41	0.69	125469.90	25358.13

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q